Quotes 5-day view End-of-day quote Nasdaq
08/05/2022
08/08/2022
08/09/2022
08/10/2022
08/11/2022
Date
1.52
1.47
1.49
1.49
1.47
Last
1194881
3506859
2475121
840616
22276020
Volume
+2.70%
-3.29%
+1.36%
0.00%
-1.34%
Change
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone...
All news about EPIZYME, INC.
2022 Ipsen completes acquisition of Epizyme expanding its portfolio in oncology AQ
2022 France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme MT
2022 Epizyme, Inc. : Termination of a Material Definitive Agreement, Completion of Acquisition .. AQ
2022 Epizyme Announces Management Changes CI
2022 Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer CI
2022 Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index CI
2022 Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index CI
2022 Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index CI
2022 Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology In.. CI
2022 Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Manag.. CI
2022 Epizyme : Reports Second Quarter 2022 Financial Results and Provides Business Update - For.. PU
2022 EPIZYME, INC. Management's Discussion and Analysis of Financial Condition and Results
.. AQ
2022 Epizyme : Q2 Earnings Snapshot AQ
2022 Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update BU
2022 Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M MT
News in other languages on EPIZYME, INC.
Analyst Recommendations on EPIZYME, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week